All In Biotech

Drug Trial Radar · NCT07432854

A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Feb 29, 2028

Study completion Jul 30, 2028

Sponsor

Lead sponsor
Dermavon Holdings LimitedIndustry
Sponsor type
Industry
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • CMS-D001 50mgDrug

    CMS-D001 50mg QD

  • CMS-D001 100mgDrug

    CMS-D001 100mg QD

  • PlaceboDrug

    Placebo QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ⅱ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)Time frame: At week 12
  2. Phase Ⅲ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)Time frame: At week 16
  3. Phase Ⅲ:Number of participants achieving a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) (PGA-TS)Time frame: At week 16

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, China

  • Shanghai Dermatology Hospital

    Shanghai, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College (Yijishan)

    Wuhu, Anhui, China

  • Southern Medical University Dermatology Hospital

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China

  • Affiliated Hospital of Hebei University of Engineering

    Handan, Hebei, China

  • Shijiazhuang Traditional Chinese Medicine Hospital

    Shijiazhuang, Hebei, China

  • The Fourth Affiliated Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shangdong, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.